Stockreport

NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]

Salarius Pharmaceuticals, Inc.  (SLRX) 
PDF This appointment reflects a pivotal step in NanOlogy's commitment to accelerating development of its LSAM drug portfolio including its development program targeting Dif [Read more]